An association of methylation of TBX2 [37] and SPRY2 [35] with disease progression has also been demonstrated in bladder cancer and B-cell diffuse lymphoma, respectively, but so far, no studies have been reported in CLL. Here, SPRY2 is linked to urinary bladder carcinoma.